Coleflux

Quick links to important sections

Coleflux

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coleflux

Coleflux is a prescription medicine with the active ingredient Simvastatin, classified as a member of the statin family of drugs, which are primarily used to correct blood lipid levels. This medication is a synthetic compound, categorized as an antilipemic agent due to its specific function in managing the blood fat profile.


Quick Facts

Property Description
Active Ingredient Simvastatin
Form Film-coated tablet
Pharmacological Class Statin (HMG-CoA Reductase Inhibitor)
Common Use Normalizing elevated blood lipids
Origin Semi-synthetic compound

What Type of Medicine is Coleflux? (Identity and Class)

Coleflux belongs to the therapeutic class of antilipemic agents, specifically functioning as a statin, which is defined as a competitive inhibitor of the HMG-CoA reductase enzyme. This classification reflects the drug's specialized role in correcting high levels of circulating lipids, such as cholesterol. The active ingredient, Simvastatin, is a semi-synthetic derivative that is clinically recognized for its established mechanism in inhibiting the enzyme responsible for cholesterol production in the liver. Coleflux is a prescription-only medication, which requires professional oversight, differentiating its controlled use from non-prescription health supplements.


Composition and Physical Form of Coleflux (Makeup and Delivery)

The active ingredient in Coleflux is Simvastatin, and it is manufactured as a single-ingredient product available for the oral route of administration in the form of a film-coated tablet. This oral dosage form is the standard presentation for statins, contrasting with specialized delivery systems. The tablet is formulated with Simvastatin and various pharmaceutical excipients that ensure its proper chemical stability and its reliable systemic delivery following ingestion. The film coating is a distinct feature designed to aid swallowing and ensure the active component is properly absorbed through the gastrointestinal tract to reach the liver.


What is the General Purpose of Taking a Statin? (High-Level Mechanism and Benefit)

The general purpose of taking a medicine like Coleflux is to normalize blood lipid levels by reducing the excessive cholesterol the body produces internally. Simvastatin achieves this by acting directly in the liver to inhibit a key enzyme that manufactures cholesterol, thereby slowing the entire production process. By controlling the amount of internal cholesterol, the medicine effectively reduces circulating Low-Density Lipoprotein Cholesterol (LDL-C)—often termed "bad cholesterol." This action on LDL-C levels helps to reduce cardiovascular risk and is understood to contribute to the long-term goal of supporting overall cardiovascular health and maintaining healthier arteries.

Regulatory References

  1. Simvastatin: MedlinePlus Drug Information | NIH

What side effects are possible with Coleflux?

Possible Side Effects and Safety Information

The regulatory safety profile for Coleflux (Simvastatin) outlines potential adverse effects classified primarily by their frequency and the body system affected. The most concentrated areas of safety concern in official documentation are the musculoskeletal system and the liver.

Adverse reactions are classified according to regulatory standards:

  • Common Reactions: These are officially listed reactions such as myalgia (muscle pain), headache, abdominal pain, constipation, nausea, and upper respiratory infection.
  • Rare Reactions: These include more serious, less frequent events like myopathy (muscle disease, including myositis), rhabdomyolysis, hepatitis, and peripheral neuropathy. Increases in serum transaminases (liver enzymes) and CK levels are also classified as rare.
  • Very Rare Reactions: Documented as occurring in less than 1 in 10,000 patients, these include fatal and non-fatal hepatic failure and anaphylaxis.

Serious Adverse Reactions

Rhabdomyolysis, a severe breakdown of muscle tissue, is documented as a serious adverse reaction that may lead to acute renal failure. Other serious concerns officially noted are fatal liver failure and a complex hypersensitivity syndrome which may involve features like angioedema and vasculitis.

Safety Patterns and Restrictions

Official labeling documents that the risk of myopathy and rhabdomyolysis is dose-dependent and increases with higher strengths. Due to this increased risk, the 80 mg daily dose is officially restricted for use only in patients who have been taking it chronically and is not recommended for new patients. Furthermore, the medicine is contraindicated in patients with active liver disease and in women who are pregnant or breastfeeding, reflecting official safety restrictions.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Manifestations

Regulatory documentation for Coleflux (Simvastatin) indicates that reported cases of acute ingestion involving high doses, including up to 3.6 g, generally resulted in patient recovery. Officially, patients in these documented scenarios recovered without sequelae, meaning there were no lasting serious consequences attributed to the acute overexposure. The official regulatory profile does not define a unique set of severe acute clinical signs or specific symptoms that reliably accompany an overdose. This evidence forms the basis for the official classification of acute risk.

Required Emergency Actions and Management

In the event of a confirmed or suspected overdose of Coleflux, the officially mandated action is to seek immediate medical attention. This urgent requirement exists because no specific antidote is known for Simvastatin, as stated in regulatory guidance. Treatment is therefore required to be symptomatic and supportive, with medical professionals implementing appropriate measures based on the patient’s clinical status. Furthermore, regulatory guidance notes that Simvastatin and its active metabolites are not dialyzable due to high protein binding, which informs the clinical decision that certain aggressive interventions are ineffective for substance elimination.

Therapeutic Uses of Coleflux

What Coleflux Treats: Main Uses and Benefits

Coleflux (Simvastatin) is primarily used to address high-risk, chronic metabolic conditions rather than providing relief for acute, perceptible symptoms. Its therapeutic benefit is centered on risk management by helping to correct key pathological markers. The use of the medication is recognized for conditions involving high cholesterol and for supportive risk control in contexts requiring cardiovascular risk mitigation.


Managing High Cholesterol and Dyslipidemia

This domain covers the primary use of Coleflux in correcting the internal metabolic pathology of elevated lipids, specifically high Low-Density Lipoprotein Cholesterol (LDL-C) and high triglycerides. The therapeutic goal is to help manage the levels of these silent blood markers, which are associated with the risk of future heart disease. The medication is commonly applied across conditions like primary hyperlipidemia, mixed dyslipidemia, and severe, inherited forms such as familial hypercholesterolemia.

Managing Cardiovascular Risk

Coleflux plays a role in managing the overall likelihood of serious vascular events, such as a non-fatal myocardial infarction or stroke. This use is highly relevant for patients with established coronary heart disease (CHD) or those facing multiple co-existing risks, like diabetes mellitus. By consistently controlling the lipid profile, the medication provides support that may assist in easing the progression of artery damage, supporting long-term heart and vascular well-being.

Quick Fact: Relief for Asymptomatic Risk
Coleflux is primarily used for long-term prevention and metabolic risk management, rather than easing immediate physical discomfort. It assists in the reduction of silent pathological markers like high LDL-C.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Coleflux? — Official Regulatory Information

The eligibility profile for Coleflux (Simvastatin) is determined by regulatory agencies based on specific patient conditions, age, and physiological status.


Populations for Whom Use is Contraindicated

Coleflux must not be used by the following groups, as stated in regulatory documents:

  • Patients with active liver disease, including those with unexplained persistent elevations of hepatic transaminases.
  • Pregnant women and nursing mothers (lactating) due to potential risk.
  • Patients with known hypersensitivity to simvastatin or any components of the preparation.

Age and Condition-Specific Eligibility Rules

Population/Condition Eligibility Status Restriction/Caution
Adults with hyperlipidemia or established CHD Allowed Standard labeled use.
Pediatric patients Conditional Approved only for ages 10 years and older with Heterozygous Familial Hypercholesterolemia (HeFH); use is not established for younger children.
Severe Renal Impairment Conditional Initial dosage must be reduced and the patient closely monitored.
80 mg Daily Dose Restricted Limited only to patients who have been stable on this dose for ge 12 months without muscle toxicity.

These rules define who may receive the medicine; for instance, the absolute prohibition for active liver disease establishes a non-negotiable eligibility bar. Other populations, such as the elderly or those with chronic alcohol use, require caution due to predisposing risk factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Coleflux (Simvastatin) has officially documented interaction patterns that primarily relate to changes in its plasma concentration and an elevated risk of muscle-related toxicity, as stated in regulatory labels. These interactions define specific restrictions and prohibitions on co-administration.

Contraindicated Combinations

The medicine is formally contraindicated (prohibited for co-use) with strong inhibitors of the CYP3A4 metabolic pathway, as this significantly increases the exposure of Simvastatin acid. Prohibited substances include certain azole antifungals, macrolide antibiotics, HIV protease inhibitors, the antilipemic agent Gemfibrozil, and the immunosuppressant Cyclosporine. The prohibition is based on the documented risk of severe myopathy.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with inhibitors of the OATP1B1 transporter, which mediates hepatic uptake, also increases systemic exposure. For certain moderate CYP3A4 inhibitors, such as Amiodarone or Verapamil, regulatory documents mandate a restriction on the maximum daily dose of Coleflux. A pharmacodynamic additive risk of muscle toxicity exists with other antilipemic agents like lipid-modifying doses of Niacin.

Other Documented Restrictions

Consumption of Grapefruit Juice must be restricted due to its inhibitory effect on the CYP3A4 pathway. Additionally, administration must be separated from Bile Acid Sequestrants to ensure proper absorption of Coleflux.

Mechanism of Action

Inhibition of Internal Cholesterol Production

Coleflux, with its active ingredient Simvastatin, functions as a competitive inhibitor of the enzyme HMG-CoA Reductase primarily within the liver. By blocking this rate-limiting step in the Mevalonate Pathway, the molecule fundamentally slows down the internal biosynthesis of cholesterol, initiating the entire chain of molecular and cellular effects.


Enhanced Systemic Clearance of LDL-C

The resulting reduction in internal cholesterol supply triggers a compensatory cellular mechanism: the liver cells increase the number of LDL-Receptors on their surface. This upregulation accelerates the capture and removal of Low-Density Lipoprotein Cholesterol (LDL-C) particles directly from the bloodstream, thus resulting in continuous reduction of circulating lipid concentration.


Modulation of Vascular Processes

Beyond lipid lowering, the drug engages secondary mechanisms known as pleiotropic effects, that modulate the function of the vascular system. These effects involve the increase of local Nitric Oxide (NO) bioavailability and modulate local inflammatory signaling pathways within the blood vessel walls.

Dosage and Administration Information

How Coleflux is Used: Official Administration Guidelines

Coleflux is administered via the oral route as a film-coated tablet and is used for long-term chronic management. The official dosing schedule mandates administration once daily and specifically in the evening, a timing designed to align with the body's lipid synthesis processes.

The standard starting dose for most adults is 10 mg or 20 mg once daily. For high-risk cardiovascular patients, the initial dose may be 40 mg once daily. The standard maximum dose that may be initiated in any new patient is 40 mg once daily. Dose adjustments, when necessary, are procedural and must be made at intervals of not less than four weeks.

Regulatory constraints apply to the highest strength: the 80 mg dose is not to be started in any new patient and is officially restricted only to individuals who have been taking it for a prolonged period (e.g., 12 months or more) without toxicity. Furthermore, when the medicine is co-administered with certain other drugs, the dose is restricted and must not exceed 10 mg per day.

Procedural requirements state that Coleflux must be used as an adjunct to a standard cholesterol-lowering diet. For patients with severe renal impairment (kidney function), the recommended starting dose is officially lowered to 5 mg once daily. If a dose is missed, it should be taken as soon as it is remembered, but the subsequent scheduled dose must not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coleflux


Research Evidence for Managing High Cholesterol (Primary Hyperlipidemia)

Coleflux (Simvastatin) was studied for its use in individuals with high levels of blood fats, specifically high Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides. The research in this area primarily consists of short-term and intermediate-term randomized controlled trials (RCTs). These studies monitored how the levels of these silent blood markers changed over time when compared to control groups.

Findings describe patterns observed in the studies where measurements of a decrease in circulating LDL-C and Total Cholesterol were described in the study findings. Shorter-term trials provided insight into short-term changes in these markers. Studies also described patterns related to measured changes in triglyceride levels. These outcomes mainly focused on the biomarker shifts themselves; these markers are generally associated with the overall risk of heart disease.

Research Evidence for Secondary Cardiovascular Risk Reduction

This part reviews the structure of long-term, large-scale randomized controlled trials conducted in individuals who already have established Coronary Heart Disease (CHD) or have experienced a heart attack. In these long-term studies, Coleflux was studied for its use in managing the risk of serious vascular events. Researchers monitored high-level endpoints such as the occurrence of non-fatal heart attack (Myocardial Infarction), stroke, and rates of death.

These trials described patterns related to fewer measured occurrences of major vascular events, including non-fatal heart attack and stroke, when compared to the control groups. This research contributes to the broader evidence landscape by describing patterns of outcomes in people with established CHD. It is important to understand that results apply only to the populations studied and that the research base is continually compared against other treatments.

Areas Where Research is Still Developing or Limited

The research base for Coleflux, while substantial, has defined limitations. Follow-up durations were limited to the specific lengths of the trials, and long-term outcomes are not fully established beyond those periods. Results apply only to the populations studied, meaning findings may not fully translate to all individuals or all comorbidity profiles. Evidence heterogeneity exists across studies, and comparative evidence is not available for all modern contexts.

Key Studies & References Cardiovascular disease: risk assessment and reduction, including lipid modification (NICE Guideline NG238)

Frequently Asked Questions (FAQ)

Common questions about Coleflux (FAQ)

Q: Can Coleflux affect my ability to drive or operate machinery?

Official product information describes rare adverse reactions, such as peripheral neuropathy (nerve damage), which may affect a person's physical function. While the regulatory labeling does not contain a specific restriction on driving or operating machinery, awareness of potential rare effects is part of the product information.

Q: Is Coleflux suitable for people who have kidney issues?

For individuals with severe renal impairment (significantly reduced kidney function), official administration guidelines describe a specific lower starting dose. The condition establishes a need for oversight and monitoring, as described in official documentation.

Q: Can Coleflux cause changes in mood or sleep patterns?

Post-marketing safety surveillance for the statin class has included reports of sleep disturbances, such as insomnia and nightmares. Less frequently, reports of depression have also been noted, reflecting the scope of ongoing regulatory monitoring.

Q: What is the possibility of long-term effects from taking Coleflux?

Official research evidence indicates that the follow-up periods in clinical trials were limited to the specific study durations. Therefore, long-term outcomes that occur beyond those established research periods are not fully established in the regulatory documentation.

Q: What if I take Coleflux on an empty stomach instead of with food?

According to official administration guidelines, Coleflux can be taken with or without food. Consistency in administration timing is an important element of the prescribed regimen.

Q: What happens if I miss a single scheduled use of Coleflux?

If a scheduled use is missed, it can be taken as soon as it is remembered. However, it is an official regulatory instruction that the subsequent scheduled dose must not be doubled to compensate for the missed one.

Q: What were the main reasons patients stopped taking Coleflux in the studies?

Clinical research reports describe that the reasons for treatment discontinuation varied among participants in studies. Common documented reasons included the patient's own decision, various types of muscle-related complaints, and confirmed drug-related adverse events.

Q: If I am unable to swallow pills, are there other forms of Coleflux available?

The active ingredient in Coleflux, Simvastatin, is officially approved and available in both a film-coated tablet and an oral suspension form.

Q: Do food interactions with Coleflux change if I take it at a different time of day?

Official administration is scheduled for the evening to align with the body's natural lipid processes. The severe restriction on grapefruit juice consumption is due to its effect on the drug's metabolism and applies regardless of the time of day the dose is taken.

Q: Is Coleflux the same kind of medicine as the older drugs for this condition?

Coleflux's active ingredient, Simvastatin, belongs to the statin class of medicines, which are all categorized as HMG-CoA Reductase Inhibitors. This classification places it within the group of established medicines used to manage blood lipid levels.

Q: Is there a generic version of Coleflux available?

Yes, the active ingredient in Coleflux is Simvastatin. This ingredient has received official approval from regulatory agencies and is available from various manufacturers as a generic version.

Q: When should I expect to notice the effects of Coleflux?

While clinical trials describe measured changes in cholesterol markers over time, a specific timeframe for patients to 'notice' the effects is not standardized in regulatory information. Documentation indicates that a healthcare provider can assess the dosage effectiveness as early as two weeks after initiation.

Q: How long does Coleflux stay in your system after you stop taking it?

Pharmacokinetic studies of the drug describe how long it remains in the body. According to official data, the active form of the drug has a rapid elimination half-life of 1 to 3 hours in the system.

Q: What happens if Coleflux is not working for me?

Regulatory information addresses the situation where the medicine does not help achieve the cholesterol goal. It describes that alternative lipid-lowering treatments are indicated instead of titrating to the highest dose for patients unable to achieve their target utilizing the 40 mg dose.

Q: Does Coleflux require any special monitoring or lab tests?

Regulatory information advises that liver enzyme tests (hepatic transaminases) should be checked prior to starting therapy. These tests are also performed periodically thereafter, as clinically indicated, according to official labeling.

Q: How is Coleflux different from the placebo used in its clinical studies?

Coleflux contains the active ingredient Simvastatin, which is a synthetic compound that acts as a potent enzyme inhibitor to lower lipids. A placebo used in clinical studies, by contrast, would contain only inactive ingredients with no pharmacological effect.

Q: How is the safety of Coleflux monitored after it has been approved?

The safety of the medicine is continuously monitored by regulatory agencies. This is achieved through mandatory post-marketing surveillance and official reporting systems for adverse events to ensure ongoing safety review of the product.

Q: What is the risk of an allergic reaction to Coleflux?

The official product information describes severe allergic events. Both anaphylaxis (a serious, rapid allergic reaction) and a complex hypersensitivity syndrome are documented as officially reported very rare reactions to the medicine.

Q: Is it normal to feel tired when starting Coleflux?

Tiredness is not listed as a common side effect in regulatory documents. However, muscle symptoms such as myalgia, which can sometimes include a feeling of weakness or fatigue, are noted as potential adverse reactions in the official product information.

How should Coleflux be stored and disposed of?

Coleflux (Simvastatin) tablets must be stored according to specific regulatory requirements to ensure product quality and safety.

Storage Domain Official Requirement
Temperature Store at controlled room temperature, generally below 25 C (77 F). Do not store above 30 C or freeze.
Environmental Protection Product must be protected from light and moisture. Keep the container tightly closed and store in a dry place.
Child Safety Keep this medicine out of the sight and reach of children.
Stability After Opening If supplied in an HDPE container, discard any unused medicine 6 months after first opening.
Disposal Do not dispose of via wastewater or household waste. Unused or expired Coleflux must be returned to a pharmacist or authorized disposal program due to environmental toxicity concerns.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coleflux found in:

A-Z Index: